Inhibition of pentose phosphate pathway suppresses acute myelogenous leukemia
- 571 Downloads
Pentose phosphate pathway (PPP) is a metabolic pathway that generates NADPH and pentose. PPP genes have been reported to be primarily or secondarily upregulated in many cancers. We aimed to study the general alteration of PPP in acute myelogenous leukemia (AML). We performed data mining and analysis of the Cancer Genome Atlas (TCGA) AML dataset for genetic alteration of the PPP gene set. In vitro studies including proliferation, migration, and invasion assays, together with metabolite consumption and oxidation assays, were performed. PPP genes were upregulated in 61 % of patients with AML. The majority of altered cases were expression changes measured by RNA sequencing. Expressions of critical PPP genes such as G6PD, PFKL, PFKP, and PGLS were consistently upregulated in all altered cases. Altered PPP is not associated with survival or disease relapse. PPP inhibition using 6-aminonicotinamide (6AN) increases glucose oxidative metabolism in AML. 6AN decreased the glucose oxidation and increased fatty acid oxidation. Here, we showed that PPP inhibition increased glucose oxidative metabolism in AML. PPP inhibition suppressed growth, migration, and invasion of AML, but not colony formation. PPP plays an important role in AML. Our results could contribute to the development of novel targeted treatment.
KeywordsPentose phosphate pathway Acute myelogenous leukemia 6-Aminonicotinamide
This study was supported in part by the International S&T Cooperation Program of China (Grant No. 2011DFA32820).
- 3.Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F: Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? Crit Rev Oncol Hematol 2015Google Scholar
- 5.Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Alkhateeb H, Zblewski D, et al. : Prognostic impact of combined npm1+/flt3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leuk Res 2015Google Scholar
- 6.Stincone A, Prigione A, Cramer T, Wamelink MM, Campbell K, Cheung E, Olin-Sandoval V, et al.: The return of metabolism: Biochemistry and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc 2014Google Scholar
- 15.Esposito A, Criscitiello C, Gelao L, Pravettoni G, Locatelli M, Minchella I, et al. : Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. Cancer Treat Rev 2015Google Scholar
- 19.Pedrosa AR, Graca JL, Carvalho S, Peleteiro MC, Duarte A, Trindade A: Notch signaling dynamics in the adult healthy prostate and in prostatic tumor development. The Prostate 2015Google Scholar